1071433-01-6

Basic information

• Product Name: Methyl 2-methylindazole-6-carboxylate
• Synonyms: Methyl 2-methylindazole-6-carboxylate;methyl 2-methyl-2H-indazole-6-carboxylate;6-(Methoxycarbonyl)-2-methyl-2H-indazole;Methyl 2-Methyl-2H-indazol-6-carboxylate;2-Methyl-2H-indazole-6-carboxylic acid methyl ester
• CAS NO: 1071433-01-6
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.1986
• Mol File: 1071433-01-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 338.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.39±0.30(Predicted)
• CAS DataBase Reference: Methyl 2-methylindazole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-methylindazole-6-carboxylate(1071433-01-6)
• EPA Substance Registry System: Methyl 2-methylindazole-6-carboxylate(1071433-01-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 1071433-01-6(Hazardous Substances Data)

Usage

Uses

2-Methyl-2H-indazole-6-carboxylic Acid Methyl Ester is a useful synthetic intermediate. It is an analog of Indazole-3-carboxylic Acid Methyl Ester (I505250) which has potential as application of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase. Indazole-3-carboxylic Acid Methyl Ester (I505250) is also used in the preparation of indazole-pyridine based protain kinase/Akt inhibitors.

Upstream product

• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 74-88-4 methyl iodide 
• 2533-69-9 methyl 2,2,2-trichloroacetimidate 

Downstream Products

• 1031417-46-5 2-methylindazole-6-carboxylic acid 

Relevant articles and documents

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

ORNITHINE DERIVATIVE

Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.